Plant-derived extracellular vesicles (PDEVs) are nanoscale lipid bilayer structures secreted by plant cells. As they possess distinctive biological advantages and therapeutic capability, PDEVs have demonstrated their considerable potential in the field of tumor treatment.
Methods
A systematic literature search was conducted across Web of Science, PubMed, and other databases using terms related to “PDEVs”, “cancer” and “drug delivery”. The studies were comprehensively analyzed to provide the up-to-date biological mechanisms.
Results
PDEVs exhibit significant anti-cancer functions by inducing cell apoptosis, arresting cell cycle progression, and enhancing anti-tumor immunity. These vesicles serve as efficient delivery platforms for endogenous and exogenous nucleic acids as well as chemotherapeutic drugs, augmenting therapeutic efficacy while reducing off-target toxicity. Emerging insights reveal PDEVs' potential as adjuvants for immunotherapy through modulating gut microbiota and related metabolites. As natural photosensitizers, PDEVs can boost photodynamic therapy efficacy. Furthermore, PDEVs can modulate the renin-angiotensin system (RAS), thereby potentially affecting tumor growth, angiogenesis, and immune responses.
Conclusions
This review highlights the prospects of PDEVs in cancer therapy by systematically summarizing their intrinsic anti-tumor effects, drug delivery capabilities, and emerging synergistic applications. This work could provide new insights into the clinical translation of PDEVs as a effective anti-cancer strategy, offering new therapeutic options for cancer patients.
HanahanD. Hallmarks of cancer: new dimensions. Cancer Discov2022; 12: 31–46.
2.
BrownJSAmendSRAustinRH, et al.Updating the definition of cancer. Mol Cancer Res2023; 21: 1142–1147.
3.
SungHFerlayJSiegelRL, et al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71: 209–249.
4.
ZhangZXieYLiuL, et al.Global, regional, and national burden of genitourinary cancers in 204 countries and territories, 1990–2021: a systematic analysis for the global burden of disease study 2021. J Natl Cancer Cent2025; 5: 330–345.
5.
JinWHuangKZhangM, et al.Global cancer burdens related to human behaviors in 1990–2044: a population-based cross-sectional and forecast study. J Natl Cancer Cent2025; 5: 346–356.
6.
LiZLiRChenJ, et al.Differences in the incidence and mortality of tracheal, bronchus, and lung cancer between the Global Cancer Observatory 2022 and the Global Burden of Disease 2021. J Natl Cancer Cent2025; 5: 267–277.
7.
WuZXiaFLinR. Global burden of cancer and associated risk factors in 204 countries and territories, 1980-2021: a systematic analysis for the GBD 2021. J Hematol Oncol2024; 17: 119.
8.
AreCMurthySSSullivanR, et al.Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide. Lancet Oncol2023; 24: e472–e518.
9.
ZhangCXuCGaoX, et al.Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics2022; 12: 2115–2132.
10.
ChandraRAKeaneFKVonckenFEM, et al.Contemporary radiotherapy: present and future. Lancet2021; 398: 171–184.
11.
LimZFMaPC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol2019; 12: 134.
12.
SiegelRLKratzerTBGiaquintoAN, et al.Cancer statistics, 2025. CA Cancer J Clin2025; 75: 10–45.
13.
VasanNBaselgaJHymanDM. A view on drug resistance in cancer. Nature2019; 575: 299–309.
14.
SongHLiuDDongS, et al.Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther2020; 5: 193.
15.
LinAGiulianoCJPalladinoA, et al.Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med2019; 11: eaaw8412.
16.
ZhaoYTanHZhangJ, et al.Plant-derived vesicles: a new era for anti-cancer drug delivery and cancer treatment. Int J Nanomedicine2023; 18: 6847–6868.
17.
MaoXLiTQiW, et al.Advances in the study of plant-derived extracellular vesicles in the skeletal muscle system. Pharmacol Res2024; 204: 107202.
18.
KaramanidouTTsouknidasA. Plant-derived extracellular vesicles as therapeutic nanocarriers. Int J Mol Sci2021; 23: 191.
19.
ZengYBDengXShenLS, et al.Advances in plant-derived extracellular vesicles: isolation, composition, and biological functions. Food Funct2024; 15: 11319–11341.
20.
WangXLiuYDongX, et al.peu-MIR2916-p3-enriched garlic exosomes ameliorate murine colitis by reshaping gut microbiota, especially by boosting the anti-colitic Bacteroides thetaiotaomicron. Pharmacol Res2024; 200: 107071.
21.
DadHAGuTWZhuAQ, et al.Plant exosome-like nanovesicles: emerging therapeutics and drug delivery nanoplatforms. Mol Ther2021; 29: 13–31.
22.
LangellottoMDRassuGSerriC, et al.Plant-derived extracellular vesicles: a synergetic combination of a drug delivery system and a source of natural bioactive compounds. Drug Deliv Transl Res2025; 15: 831–845.
23.
LouKLuoHJiangX, et al.Applications of emerging extracellular vesicles technologies in the treatment of inflammatory diseases. Front Immunol2024; 15: 1364401.
24.
KimMJangHKimW, et al.Therapeutic applications of plant-derived extracellular vesicles as antioxidants for oxidative stress-related diseases. Antioxidants (Basel)2023; 12: 1286.
25.
TrentiniMZanollaITiengoE, et al.Link between organic nanovesicles from vegetable kingdom and human cell physiology: intracellular calcium signalling. J Nanobiotechnology2024; 22: 68.
26.
QiangWLiJRuanR, et al.Plant-derived extracellular vesicles as a promising anti-tumor approach: a comprehensive assessment of effectiveness, safety, and mechanisms. Phytomedicine2024; 130: 155750.
27.
ChuKLiuJZhangX, et al.Herbal medicine-derived exosome-like nanovesicles: a rising star in cancer therapy. Int J Nanomedicine2024; 19: 7585–7603.
28.
KaimuangpakKTamprasitKThumanuK, et al.Extracellular vesicles derived from microgreens of Raphanus sativus L. var. caudatus Alef contain bioactive macromolecules and inhibit HCT116 cells proliferation. Sci Rep2022; 12: 15686.
29.
TanZLLiJFLuoHM, et al.Plant extracellular vesicles: a novel bioactive nanoparticle for tumor therapy. Front Pharmacol2022; 13: 1006299.
30.
FengJXiuQHuangY, et al.Plant-derived vesicle-like nanoparticles as promising biotherapeutic tools: present and future. Adv Mater2023; 35: e2207826.
31.
CongMTanSLiS, et al.Technology insight: plant-derived vesicles-how far from the clinical biotherapeutics and therapeutic drug carriers?Adv Drug Deliv Rev2022; 182: 114108.
32.
KürtösiBKazsokiAZelkóR. A systematic review on plant-derived extracellular vesicles as drug delivery systems. Int J Mol Sci2024; 25: 7559.
ShaALuoYXiaoW, et al.Plant-derived exosome-like nanoparticles: a comprehensive overview of their composition, biogenesis, isolation, and biological applications. Int J Mol Sci2024; 25: 12092.
35.
LianMQChngWHLiangJ, et al.Plant-derived extracellular vesicles: recent advancements and current challenges on their use for biomedical applications. J Extracell Vesicles2022; 11: e12283.
36.
XuZXuYZhangK, et al.Plant-derived extracellular vesicles (PDEVs) in nanomedicine for human disease and therapeutic modalities. J Nanobiotechnology2023; 21: 114.
37.
LiMWangCLiuH, et al.MiRNAs in cancers and renin-angiotensin-aldosterone system: implications for chemoradiotherapy resistance. J Renin Angiotensin Aldosterone Syst2025; 26: 14703203251367136.
38.
WuHShiMMengL, et al.Plant-derived extracellular vesicles as a novel tumor-targeting delivery system for cancer treatment. Front Cell Dev Biol2025; 13: 1589550.
39.
KimJLiSZhangS, et al.Plant-derived exosome-like nanoparticles and their therapeutic activities. Asian J Pharm Sci2022; 17: 53–69.
40.
FanSJChenJYTangCH, et al.Edible plant extracellular vesicles: an emerging tool for bioactives delivery. Front Immunol2022; 13: 1028418.
41.
HatsugaiNHara-NishimuraI. Two vacuole-mediated defense strategies in plants. Plant Signal Behav2010; 5: 1568–1570.
42.
FangZLiuK. Plant-derived extracellular vesicles as oral drug delivery carriers. J Control Release2022; 350: 389–400.
43.
LiuYXiaoSWangD, et al.A review on separation and application of plant-derived exosome-like nanoparticles. J Sep Sci2024; 47: e2300669.
44.
WangJDingYWangJ, et al.EXPO, an exocyst-positive organelle distinct from multivesicular endosomes and autophagosomes, mediates cytosol to cell wall exocytosis in Arabidopsis and tobacco cells. Plant Cell2010; 22: 4009–4030.
45.
GaoCChenYWenX, et al.Plant-derived exosome-like nanoparticles in tissue repair and regeneration. J Mater Chem B2025; 13: 2254–2271.
46.
NueraihemaitiNDilimulatiDBaishanA, et al.Advances in plant-derived extracellular vesicle extraction methods and pharmacological effects. Biology (Basel)2025; 14: 377.
47.
ZhangMViennoisEXuC, et al.Plant derived edible nanoparticles as a new therapeutic approach against diseases. Tissue Barriers2016; 4: e1134415.
48.
ShaoMJinXChenS, et al.Plant-derived extracellular vesicles -a novel clinical anti-inflammatory drug carrier worthy of investigation. Biomed Pharmacother2023; 169: 115904.
49.
ZhuYZhouXYaoZ. A mini-review: advances in plant-derived extracellular vesicles as nano-delivery systems for tumour therapy. Front Bioeng Biotechnol2022; 10: 1076348.
50.
WangRZhangYGuoY, et al.Plant-derived nanovesicles: promising therapeutics and drug delivery nanoplatforms for brain disorders. Fundam Res2025; 5: 830–850.
51.
LiuXLouKZhangY, et al.Unlocking the medicinal potential of plant-derived extracellular vesicles: current progress and future perspectives. Int J Nanomedicine2024; 19: 4877–4892.
52.
CuiLPeriniGPalmieriV, et al.Plant-derived extracellular vesicles as a novel frontier in cancer therapeutics. Nanomaterials (Basel)2024; 14: 1331.
53.
AlfieriMLeoneAAmbrosoneA. Plant-derived nano and microvesicles for human health and therapeutic potential in nanomedicine. Pharmaceutics2021; 13: 498.
54.
WeiCZhangMChengJ, et al.Plant-derived exosome-like nanoparticles - from laboratory to factory, a landscape of application, challenges and prospects. Crit Rev Food Sci Nutr2025; 65: 4510–4528.
55.
BedouiSHeroldMJStrasserA. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol2020; 21: 678–695.
56.
JoshiASBapatMVSinghP, et al.Viridibacillus culture derived silver nanoparticles exert potent anticancer action in 2D and 3D models of lung cancer via mitochondrial depolarization-mediated apoptosis. Mater Today Bio2024; 25: 100997.
57.
AtefAAAIsmailSMASaeedAAM. Synergistic anticancer effects of Dracaena cinnabari and Aloe perryi extracts on colorectal cancer cells: a flow cytometry analysis of toxicity, cell cycle, apoptosis, and autophagy. Lett Drug Des Discov2025; 22: 100196.
58.
NagataS. Apoptosis and clearance of apoptotic cells. Annu Rev Immunol2018; 36: 489–517.
59.
MitraPJanaSDasP, et al.Sida cordifolia L. fraction ameliorate renal injury, inflammation, apoptosis and gene expression on cisplatin induced acute kidney injury: network pharmacology, in vivo and in vitro studies. Curr Pharm Anal2025; 21: 281–300.
60.
AmirinejadMEftekhar-VaghefiSHNematollahi MahaniSN, et al.Exposure to low-frequency radiation changes the expression of nestin, VEGF, BCRP and apoptosis markers during glioma treatment strategy: an in vitro study. Curr Radiopharm2024; 17: 55–67.
61.
MartinouJCYouleRJ. Mitochondria in apoptosis: bcl-2 family members and mitochondrial dynamics. Dev Cell2011; 21: 92–101.
62.
KesavardhanaSMalireddiRKSKannegantiTD. Caspases in cell death, inflammation, and pyroptosis. Annu Rev Immunol2020; 38: 567–595.
63.
YuanJOfengeimD. A guide to cell death pathways. Nat Rev Mol Cell Biol2024; 25: 379–395.
64.
FanHWangCLiuS, et al.Therapeutic potential of natural products in stress granules: underlying molecular mechanisms and future perspectives. Curr Pharm Anal2025; 21: 88–99.
65.
MacheretMHalazonetisTD. DNA Replication stress as a hallmark of cancer. Annu Rev Pathol2015; 10: 425–448.
66.
WongRS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res2011; 30: 87.
67.
SulimanALamADattaR, et al.Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene2001; 20: 2122–2133.
68.
CarneiroBAEl-DeiryWS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol2020; 17: 395–417.
69.
AtasoyOAnadolEYar SaglamAS, et al.Synergistic potential of GLP-1 receptor agonists and radiotherapy in breast cancer treatment: a new therapeutic avenue (TROD-GROG 006). Curr Radiopharm2025; 18: 318–332.
70.
BahadoranEZafariYHomaeiA, et al.Role of the p53/miR-34a/SIRT1 feedback loop in metformin-induced radiosensitivity of colorectal cancer cells. Curr Radiopharm2025; 18: 340–351.
71.
WongkaewkhiawSWongrakpanichAKrobthongS, et al.Induction of apoptosis in human colorectal cancer cells by nanovesicles from fingerroot (Boesenbergia rotunda (L.) Mansf.). PLoS One2022; 17: e0266044.
72.
ZhangLHeFGaoL, et al.Engineering exosome-like nanovesicles derived from asparagus cochinchinensis can inhibit the proliferation of hepatocellular carcinoma cells with better safety profile. Int J Nanomedicine2021; 16: 1575–1586.
73.
WangFLiLDengJ, et al.Lipidomic analysis of plant-derived extracellular vesicles for guidance of potential anti-cancer therapy. Bioact Mater2025; 46: 82–96.
74.
ChintapulaUOhDPerezC, et al.Anti-cancer bioactivity of sweet basil leaf derived extracellular vesicles on pancreatic cancer cells. J Extracell Biol2024; 3: e142.
75.
ChenQZuMGongH, et al.Tea leaf-derived exosome-like nanotherapeutics retard breast tumor growth by pro-apoptosis and microbiota modulation. J Nanobiotechnology2023; 21: 6.
76.
ChenQLiQLiangY, et al.Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation. Acta Pharm Sin B2022; 12: 907–923.
77.
RaimondoSNaselliFFontanaS, et al.Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death. Oncotarget2015; 6: 19514–19527.
78.
ÖzkanİKoçakPYıldırımM, et al.Garlic (Allium sativum)-derived SEVs inhibit cancer cell proliferation and induce caspase mediated apoptosis. Sci Rep2021; 11: 14773.
79.
KaimuangpakKRosalinaRThumanuK, et al.Macromolecules with predominant β-pleated sheet proteins in extracellular vesicles released from Raphanus sativus L. var. caudatus Alef microgreens induce DNA damage-mediated apoptosis in HCT116 colon cancer cells. Int J Biol Macromol2024; 269: 132001.
80.
BocciaEAlfieriMBelvedereR, et al.Plant hairy roots for the production of extracellular vesicles with antitumor bioactivity. Commun Biol2022; 5: 848.
81.
LigasováAFrydrychIKobernaK. Basic methods of cell cycle analysis. Int J Mol Sci2023; 24: 3674.
82.
HuangYSunWZhuD, et al.RBM3 Inhibits the cell cycle of cutaneous squamous cell carcinoma through the PI3K/AKT signaling pathway. Curr Mol Pharmacol2024; 17: e18761429323760.
83.
RoskoskiRJr. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol Res2019; 139: 471–488.
84.
XieBWangSJiangN, et al.Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett2019; 443: 56–66.
85.
ZhangCLiuJXuD, et al.Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol2020; 12: 674–687.
86.
SmithHLSouthgateHTweddleDA, et al.DNA Damage checkpoint kinases in cancer. Expert Rev Mol Med2020; 22: e2.
87.
MatthewsHKBertoliCde BruinRAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol2022; 23: 74–88.
88.
EngelandK. Cell cycle arrest through indirect transcriptional repression by p53: i have a DREAM. Cell Death Differ2018; 25: 114–132.
89.
ChenTMaBLuS, et al.Cucumber-derived nanovesicles containing cucurbitacin B for non-small cell lung cancer therapy. Int J Nanomedicine2022; 17: 3583–3599.
90.
HuangJCaoXWuW, et al.Investigating the proliferative inhibition of HepG2 cells by exosome-like nanovesicles derived from Centella asiatica extract through metabolomics. Biomed Pharmacother2024; 176: 116855.
91.
YangMLuoQChenX, et al.Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma. J Nanobiotechnology2021; 19: 259.
92.
StanlyCAlfieriMAmbrosoneA, et al.Grapefruit-derived micro and nanovesicles show distinct metabolome profiles and anticancer activities in the A375 human melanoma cell line. Cells2020; 9: 2722.
93.
ShkrylYTsydeneshievaZMenchinskayaE, et al.Exosome-like nanoparticles, high in trans-δ-viniferin derivatives, produced from grape cell cultures: preparation, characterization, and anticancer properties. Biomedicines2024; 12: 2142.
94.
YangMLiuXLuoQ, et al.An efficient method to isolate lemon derived extracellular vesicles for gastric cancer therapy. J Nanobiotechnology2020; 18: 100.
95.
TajikTBaghaeiKMoghadamVE, et al.Extracellular vesicles of cannabis with high CBD content induce anticancer signaling in human hepatocellular carcinoma. Biomed Pharmacother2022; 152: 113209.
96.
ChenLLinATangB, et al.The future of cancer therapy: nanomaterials and tumor microenvironment. iMetaMed2025; 1: e70007.
97.
FangYKongYRongG, et al.Systematic investigation of tumor microenvironment and antitumor immunity with IOBR. Med Res2025; 1: 136–140.
98.
GaoZJiangALiZ, et al.Heterogeneity of intratumoral microbiota within the tumor microenvironment and relationship to tumor development. Med Res2025; 1: 32–61.
99.
XiaoYYuD. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther2021; 221: 107753.
100.
BaoXSunMMengL, et al.Applications of pyroptosis activators in tumor immunotherapy. Mater Today Bio2024; 28: 101191.
101.
XuZZhouHLiT, et al.Application of biomimetic nanovaccines in cancer immunotherapy: a useful strategy to help combat immunotherapy resistance. Drug Resist Updat2024; 75: 101098.
102.
JiangQHeJZhangH, et al.Recent advances in the development of tumor microenvironment-activatable nanomotors for deep tumor penetration. Mater Today Bio2024; 27: 101119.
103.
ZhuYHuYYangC, et al.Progress of angiogenesis signal pathway and antiangiogenic drugs in nasopharyngeal carcinoma. Curr Mol Pharmacol2024; 17: e18761429290933.
104.
ZhangQSioudM. Tumor-associated macrophage subsets: shaping polarization and targeting. Int J Mol Sci2023; 24: 7493.
105.
ZhangYZhangHFangY, et al.Emerging role of tumor associated macrophages in pan-tumor progression: biological mechanisms to clinical application. Curr Proteomics2025; 22: 100052.
106.
LiuZLiuXWangJ. From stem cells to therapeutics: advancing islet function restoration through mesenchymal stem cell-based drug research. Lett Drug Des Discov2025; 22: 100146.
107.
LinACheCChenL, et al.Immune checkpoint modulators in cancer immunotherapy from inhibition to activation. Curr Proteomics2025; 22: 100056.
108.
ZhangJMaoYZhangY, et al.Efficacy and safety of PD-1/PD-L1 inhibitors for relapsed/metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Lett Drug Des Discov2025; 22: 100128.
109.
LinYXuJLanH. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol2019; 12: 76.
110.
WangXWangCLiuW, et al.The roles of ultrasound-responsive nanomaterials in enhancing cancer immunotherapy. Pharmacol Res2025; 221: 107975.
111.
XiaFYiQXuZ, et al.Microbial modulation as a game changer: boosting immunotherapy efficacy in breast cancer. Semin Cancer Biol2025; 117: 152–167.
112.
BaoYLiGLiS, et al.A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade. Mater Today Bio2024; 29: 101346.
113.
ZhengGWuSDengX, et al.Lanthanum-based dendritic mesoporous nanoplatform for tumor microenvironment activating synergistic anti-glioma efficacy. Mater Today Bio2024; 28: 101223.
114.
VadevooSMPKangYGunassekaranGR, et al.IL4 Receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis. Theranostics2024; 14: 2605–2621.
115.
YangMGuoJLiJ, et al.Platycodon grandiflorum-derived extracellular vesicles suppress triple-negative breast cancer growth by reversing the immunosuppressive tumor microenvironment and modulating the gut microbiota. J Nanobiotechnology2025; 23: 92.
116.
KimJZhuYChenS, et al.Anti-glioma effect of ginseng-derived exosomes-like nanoparticles by active blood-brain-barrier penetration and tumor microenvironment modulation. J Nanobiotechnology2023; 21: 253.
117.
CaoMYanHHanX, et al.Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth. J Immunother Cancer2019; 7: 326.
118.
AlzahraniFAKhanMIKameliN, et al.Plant-derived extracellular vesicles and their exciting potential as the future of next-generation drug delivery. Biomolecules2023; 13: 839.
119.
YangLYLiangGWCaiBJ, et al.Enhanced tumor self-targeting of lemon-derived extracellular vesicles by embedding homotypic cancer cell membranes for efficient drug delivery. J Nanobiotechnology2025; 23: 74.
120.
PiFBinzelDWLeeTJ, et al.Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol2018; 13: 82–89.
121.
WangQZhuangXMuJ, et al.Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun2013; 4: 1867.
122.
HaoSYangHHuJ, et al.Bioactive compounds and biological functions of medicinal plant-derived extracellular vesicles. Pharmacol Res2024; 200: 107062.
ZhangMViennoisEPrasadM, et al.Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials2016; 101: 321–340.
125.
LiuHSongJZhouL, et al.Construction of curcumin-fortified juices using their self-derived extracellular vesicles as natural delivery systems: grape, tomato, and orange juices. Food Funct2023; 14: 9364–9376.
126.
GaiCPomattoMACDeregibusMC, et al.Edible plant-derived extracellular vesicles for oral mRNA vaccine delivery. Vaccines (Basel)2024; 12: 200.
127.
LvLLiZLiuX, et al.Revolutionizing medicine: harnessing plant-derived vesicles for therapy and drug transport. Heliyon2024; 10: e40127.
128.
ZhaoBLinHJiangX, et al.Exosome-like nanoparticles derived from fruits, vegetables, and herbs: innovative strategies of therapeutic and drug delivery. Theranostics2024; 14: 4598–4621.
129.
ChinARFongMYSomloG, et al.Cross-kingdom inhibition of breast cancer growth by plant miR159. Cell Res2016; 26: 217–228.
130.
LiuYDChenHRZhangY, et al.Progress and challenges of plant-derived nucleic acids as therapeutics in macrophage-mediated RNA therapy. Front Immunol2023; 14: 1255668.
131.
FabianMRSonenbergNFilipowiczW. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem2010; 79: 351–379.
132.
DjuranovicSNahviAGreenR. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science2012; 336: 237–240.
133.
YiCLuLLiZ, et al.Plant-derived exosome-like nanoparticles for microRNA delivery in cancer treatment. Drug Deliv Transl Res2025; 15: 84–101.
134.
XiaoJFengSWangX, et al.Identification of exosome-like nanoparticle-derived microRNAs from 11 edible fruits and vegetables. PeerJ2018; 6: e5186.
135.
KantarcıoğluMYıldırımGAkpınar OktarP, et al.Coffee-derived exosome-like nanoparticles: are they the secret heroes?Turk J Gastroenterol2023; 34: 161–169.
136.
FengXLuoQZhangH, et al.The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. J Exp Clin Cancer Res2017; 36: 81.
137.
YanGXiaoQZhaoJ, et al.Brucea javanica derived exosome-like nanovesicles deliver miRNAs for cancer therapy. J Control Release2024; 367: 425–440.
138.
PotestàMRogliaVFanelliM, et al.Effect of microvesicles from Moringa oleifera containing miRNA on proliferation and apoptosis in tumor cell lines. Cell Death Discov2020; 6: 43.
139.
WangXWuBSunG, et al.Selenium biofortification enhanced miR167a expression in broccoli extracellular vesicles inducing apoptosis in human pancreatic cancer cells by targeting IRS1. Int J Nanomedicine2023; 18: 2431–2446.
140.
UrzìOGasparroRGanjiNR, et al.Plant-RNA in extracellular vesicles: the secret of cross-kingdom communication. Membranes (Basel)2022; 12: 352.
141.
López de las HazasM-CTomé-CarneiroJdel Pozo-AceboL, et al.Therapeutic potential of plant-derived extracellular vesicles as nanocarriers for exogenous miRNAs. Pharmacol Res2023; 198: 106999.
142.
ZhuangXTengYSamykuttyA, et al.Grapefruit-derived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression. Mol Ther2016; 24: 96–105.
143.
TengYMuJHuX, et al.Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget2016; 7: 25683–25697.
144.
CorvignoSLiuYBayraktarE, et al.Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy. NPJ Precis Oncol2024; 8: 86.
145.
UbanakoPMirzaSRuffP, et al.Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges. Front Mol Biosci2024; 11: 1447953.
146.
AnthiyaSÖztürkSCYanikH, et al.Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. J Control Release2023; 357: 67–83.
147.
Rabienezhad GanjiNUrzìOTinnirelloV, et al.Proof-of-concept study on the use of tangerine-derived nanovesicles as siRNA delivery vehicles toward colorectal cancer cell line SW480. Int J Mol Sci2023; 25: 546.
148.
LiZWangHYinH, et al.Arrowtail RNA for ligand display on ginger exosome-like nanovesicles to systemic deliver siRNA for cancer suppression. Sci Rep2018; 8: 14644.
149.
D'AngeloNANoronhaMACâmaraMCC, et al.Doxorubicin nanoformulations on therapy against cancer: an overview from the last 10 years. Biomater Adv2022; 133: 112623.
150.
Ibrahim FouadGAhmedKA. Curcumin ameliorates doxorubicin-induced cardiotoxicity and hepatotoxicity via suppressing oxidative stress and modulating iNOS, NF-κB, and TNF-α in rats. Cardiovasc Toxicol2022; 22: 152–166.
151.
StećATargońskaMJaikishanS, et al.Incorporation of doxorubicin into plant-derived nanovesicles: process monitoring and activity assessment. Drug Deliv2025; 32: 2439272.
152.
ZhangMXiaoBWangH, et al.Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol Ther2016; 24: 1783–1796.
153.
LuXHanQChenJ, et al.Celery (Apium graveolens L.) exosome-like nanovesicles as a new-generation chemotherapy drug delivery platform against tumor proliferation. J Agric Food Chem2023; 71: 8413–8424.
154.
NiuWXiaoQWangX, et al.A biomimetic drug delivery system by integrating grapefruit extracellular vesicles and doxorubicin-loaded heparin-based nanoparticles for glioma therapy. Nano Lett2021; 21: 1484–1492.
155.
TengYLuoCQiuX, et al.Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites. Nat Commun2025; 16: 1295.
156.
ZhangHChenHYinS, et al.Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation. J Nutr Biochem2023; 112: 109186.
157.
ZhuLJChenXQLinQY, et al.Ginseng-derived exosomes attenuate immune evasion in NSCLC via PD-L1 modulation. Cancer Manag Res2025; 17: 1503–1512.
158.
WanYFuLHLiC, et al.Conquering the hypoxia limitation for photodynamic therapy. Adv Mater2021; 33: e2103978.
159.
MaXChenNZengP, et al.Hypericum perforatum-derived exosomes-like nanovesicles: a novel natural photosensitizer for effective tumor photodynamic therapy. Int J Nanomedicine2025; 20: 1529–1541.
160.
CalzoniEBertoldiACesarettiA, et al.Aloe extracellular vesicles as carriers of photoinducible metabolites exhibiting cellular phototoxicity. Cells2024; 13: 1845.
161.
ShenJHuangY-MWangM, et al.Renin-angiotensin system blockade for the risk of cancer and death. J Renin Angiotensin Aldosterone Syst2016; 17: 1470320316656679.
162.
ParkYKangDSinnDH, et al.Effect of renin-angiotensin system inhibitor in incident cancer among chronic hepatitis B patients: an emulated target trial using a nationwide cohort. J Renin Angiotensin Aldosterone Syst2024; 25: 14703203241294037.
163.
HassaniBAttarZFirouzabadiN. The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies. Cancer Cell Int2023; 23: 254.
164.
LaghlamDJozwiakMNguyenLS. Renin-angiotensin-aldosterone system and immunomodulation: a state-of-the-art review. Cells2021; 10: 1767.
Wegman-OstroskyTSoto-ReyesEVidal-MillánS, et al.The renin-angiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst2015; 16: 227–233.
167.
AfsarBAfsarREErtugluLA, et al.Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics. Clin Transl Oncol2021; 23: 682–696.
168.
AlmutlaqMAlamroAAAlamriHS, et al.The effect of local renin angiotensin system in the common types of cancer. Front Endocrinol (Lausanne)2021; 12: 736361.
169.
YangKZhouJChenY, et al.Angiotensin II contributes to intratumoral immunosuppression via induction of PD-L1 expression in non-small cell lung carcinoma. Int Immunopharmacol2020; 84: 106507.
170.
ArjmandMH. Elucidating the association between the upregulation of angiotensin type 1-receptors and the development of gastrointestinal malignancies. J Gastrointest Cancer2021; 52: 399–406.
171.
BaderMSteckelingsUMAleninaN, et al.Alternative renin-angiotensin system. Hypertension2024; 81: 964–976.
172.
PatelYThapaPPrajapatiA. New insights into prostate cancer from the renin-angiotensin-aldosterone system. Cell Signal2024; 124: 111442.
173.
YuCTangWWangY, et al.Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry. Cancer Lett2016; 376: 268–277.
174.
XuJFanJWuF, et al.The ACE2/angiotensin-(1-7)/Mas receptor axis: pleiotropic roles in cancer. Front Physiol2017; 8: 276.
175.
DongFLiHLiuL, et al.ACE2 Negatively regulates the Warburg effect and suppresses hepatocellular carcinoma progression via reducing ROS-HIF1α activity. Int J Biol Sci2023; 19: 2613–2629.
176.
FanFTianCTaoL, et al.Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway. Biomed Pharmacother2016; 83: 704–711.
177.
SinghASrivastavaNYadavA, et al.Targeting AGTR1/NF-κB/CXCR4 axis by miR-155 attenuates oncogenesis in glioblastoma. Neoplasia2020; 22: 497–510.
178.
NakamuraKYaguchiTOhmuraG, et al.Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. Cancer Sci2018; 109: 54–64.
179.
PeriniMVDmelloRSNeroTL, et al.Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. Pharmacol Ther2020; 211: 107527.
180.
XiePGuoLYuQ, et al.ACE2 Enhances sensitivity to PD-L1 blockade by inhibiting macrophage-induced immunosuppression and angiogenesis. Cancer Res2025; 85: 299–313.
181.
FortuneKAliSMasurJ, et al.Impact of renin-angiotensin system inhibitors on response to PD1/L1 inhibitors in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer2025; 23: 102256.
182.
HuFRaoMZhangM, et al.Long non-coding RNA profiles in plasma exosomes of patients with gastric high-grade intraepithelial neoplasia. Exp Ther Med2022; 23: 1.
183.
PedrosaMALabandeiraCMLago-BaameiroN, et al.Extracellular vesicles and their renin-angiotensin cargo as a link between metabolic syndrome and Parkinson's disease. Antioxidants (Basel)2023; 12: 2045.
184.
XiaoMZengWWangJ, et al.Exosomes protect against acute myocardial infarction in rats by regulating the renin-angiotensin system. Stem Cells Dev2021; 30: 622–631.
185.
LyuLWangHLiB, et al.A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes. J Mol Cell Cardiol2015; 89: 268–279.
JamshidiEBabajaniASoltaniP, et al.Proposed mechanisms of targeting COVID-19 by delivering mesenchymal stem cells and their exosomes to damaged organs. Stem Cell Rev Rep2021; 17: 176–192.
188.
YiQXuZThakurA, et al.Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment. Pharmacol Res2023; 190: 106733.
189.
KameliNDragojlovic-KerkacheASavelkoulP, et al.Plant-derived extracellular vesicles: current findings, challenges, and future applications. Membranes (Basel)2021; 11: 411.
190.
SongYKongHOhS, et al.Plant-derived extracellular vesicles as nanocarriers for combination therapy enhancing paclitaxel-based regimens in breast cancer. BMB Rep2025; 58: 53–63.
191.
TinnirelloVRabienezhad GanjiNDe Marcos LousaC, et al.Exploiting the opportunity to use plant-derived nanoparticles as delivery vehicles. Plants (Basel)2023; 12: 1207.
192.
LoKJWangMHHoCT, et al.Plant-derived extracellular vesicles: a new revolutionization of modern healthy diets and biomedical applications. J Agric Food Chem2024; 72: 2853–2878.
193.
HanXZhengWSunZ, et al.Plant-derived exosomes: unveiling the similarities and disparities between conventional extract and innovative form. Phytomedicine2025; 145: 157087.
194.
WangYWangJMaJ, et al.Focusing on future applications and current challenges of plant derived extracellular vesicles. Pharmaceuticals (Basel)2022; 15: 708.
195.
OreficeNSDi RaimoRMizzoniD, et al.Purposing plant-derived exosomes-like nanovesicles for drug delivery: patents and literature review. Expert Opin Ther Pat2023; 33: 89–100.
196.
ZhuYZhaoJDingH, et al.Applications of plant-derived extracellular vesicles in medicine. MedComm (2020)2024; 5: e741.
197.
TemboKMWangXBolideeiM, et al.Exploring the bioactivity of MicroRNAs originated from plant-derived exosome-like nanoparticles (PELNs): current perspectives. J Nanobiotechnology2025; 23: 563.
198.
SongYFengNYuQ, et al.Exosomes in disease therapy: plant-derived exosome-like nanoparticles current status, challenges, and future prospects. Int J Nanomedicine2025; 20: 10613–10644.
